RET and lung carcinoma: Furthermore, the lung cancer cell line Lc2/ad, which carries a RET fusion, shows more resistance to erlotinib compared to SW48 cells, and direct targeting of RET inhibition in Lc2/ad cells can be bypassed by EGFR activation34,35.